PCN86 Healthcare Costs and Resource Utilization Associated with PARP Inhibitors in Ovarian Cancer Patients Initially Treated with Platinum-Based Therapy
Dec 1, 2020, 00:00 AM
10.1016/j.jval.2020.08.223
https://www.valueinhealthjournal.com/article/S1098-3015(20)32479-7/fulltext
Section Title :
Section Order :
10172
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)32479-7&doi=10.1016/j.jval.2020.08.223